Persona
CONSIGLIO ANTONELLA
Course Catalogue:
Curriculum Vitae
ANTONELLA CONSIGLIO
Ricercatore di Biochimica Clinica e Biologia Molecolare Clinica,
Dipartimento di Scienze Biomediche e Biotecnologiche,
Viale Europa, 11-25123 Brescia
Telefono: 030/3717.553 – 030/3717.545-561
Fax: 030/3701157
E-mail: consiglio@med.unibs.it aconsiglio@ibub.pcb.ub.es
Consiglio lab uses stem cells, mainly patient-derived induced pluripotent stem cells (iPSCs) derived from idiopathic and familial PD skin cells and healthy age-matched controls, aiming to decipher the mechanisms that lead to PD brain cell dysfunction and degeneration. The lab is also developing novel technologies in stem cells, genetic cell reprogramming and CRISPR/Cas9 gene editing for modeling other neurodegenerative diseases as well as exploring the potential of iPSC-based strategies for biomedical applications for neurodegenerative diseases, in particular for PD.
Dr. Consiglio received her PhD degree in Cellular and Molecular Pathology at the San Raffaele Scientific Hospital, DIBIT (Italy), and additional training at Gene Therapy Center of Lausanne (Switzerland) and Vectors Technology Laboratory at Cell Genesys (Foster City, CA). She did her Postdoctoral research at the Salk Institute for Biological Studies in La Jolla (USA) in the laboratory of one of the leaders in the neurogenesis field, Prof. F.H. Gage. From 2006 to 2009 Dr. Consiglio conducted her research in the Center of Regenerative Medicine in Barcelona (CMRB), where she started a close collaboration with the group directed by Prof. J.C. Izpisúa-Belmonte. During this period, she made notable contributions to the fields of neurogenesis, as well as pluripotent stem cell biology and neural differentiation that resulted in publications in top-tier scientific journals. In addition, Dr. Consiglio and her team carried out specific projects aimed at uncovering the signaling molecules that instruct neural stem/progenitor cells to differentiate toward specific cell types. Among the contributions from this research period are: the successful derivation and characterisation of hES cell lines, (CSH, 2008), and the efficient generation of iPSCs from human keratinocytes (Nat. Biotech, 2008, Genes & Development, 2010), and 3. the first generation of patient- specific iPSCs (Nature, 2009). Other studies examined the developmental potential of iPS cells necessary to validate their usage in cell replacement strategies (Aging Cell, 2012; Stem Cell Dev., 2012). Interestingly, her research group unequivocally demonstrated that stable genetic engineering of hESC/iPSC with lentiviral vectors driving controlled expression of LMX1A is an efficient way to generate enriched populations of human A9-subtype ventral midbrain DA neurons that can survive and differentiate when grafted into the brain of adult mice (Human Gene Therapy, 2012).
In 2013 A. Consiglio has been awarded a European Research Council (ERC) Starting Independent Researcher by the EU. Some of the scientific highlights of the group within the last five years include the study of how neural stem cells can be directed to mature functioning nerve cells in the adult brain and their potential in physiology and disease. By using several approaches, including exogenously regulated expression, LV-mediated siRNA delivery, constitutive, conditional and self- excising LV mediated delivery, the function of several candidate genes have been investigated in vivo to explore new strategies for the selective amplification of transduced cells, forced differentiation toward cell lineages or forced migration toward diseases sites (Nat. Cell Biology, 2014). In addition, Consiglio lab in collaboration with the group of Dr. Angel Raya (Center of Regenerative Medicine in Barcelona), and Dr. Eduard Tolosa (Hospital Clinic, Barcelona) developed a human cell-based model for PD using induced pluripotent stem cells (iPSC) from patients suffering sporadic or familial PD, and age-matched controls, to generate patient-specific dopamine neurons (DAn). Interestingly we found that patients’ DAn show PD-relevant phenotypes such as abnormal α-synuclein accumulation, alterations in the autophagy machinery, and increased susceptibility to undergo neurodegeneration upon long-term culture. All our achievements collected in the recent studies, confirm the possibility that the new developed PD humanized in vitro model will allow the straightforward investigation of the cellular defects associated with PD providing an ideal setting for future systematic drug screenings. The results of the research team during the last five years have been published in several international peer-reviewed journals (EMBO Mol. Med, 2012; Nat. Neurosc., 2013; EMBO Mol. Med. 2015; Stem Cell Reports, 2015; Molecular Neurobiology, 2018; Cell Reports, under revision).
Dr. Consiglio is a reviewer for several journals including: Nature, Nature Neuroscience, Neurobiology of Disease, Scientific Reports, PNAS, Autophagy, Neurology and Brain. She also acted as Ad-hoc reviewer for funding agencies including: ANEP (Spanish National Agency for Grant Evaluation); AGAUR (Catalonian Agency for Grant Evaluation); INSERM (France); Italian Ministry of Instruction, University and Research (MIUR), TELETHON (Italy) and European Research Council (ERC).
Dr. Consiglio is member of several societies including: American Society of Gene and Cell Therapy (since 2000); European Society of Gene and Cell Therapy (since 2008), Society for Neuroscience (since 2003), International Society for Stem Cell Research (since 2008), FENS (since 2010); Italian Society for Neuroscience (SINS, Italy) (since 2007): Spanish Society for Cell and Gene Therapy (since 2012). Antonella Consiglio is also a Founder and Board Member of the Stem Cell Research (SCR, Italy).
On the last topics, Dr. Consiglio’s group has recently provided the first direct experimental evidence that astrocytes from PD patients not only produce significantly more α-synuclein than astrocytes from healthy individuals, but also manifest many pathological changes typical of PD. Interestingly, PD astrocytes contribute to a selective vmDA neuronal cell death, suggesting that they play a key role in the early stages of the disease. A manuscript reporting these ground-breaking observations is currently in the second revision stage in Cell Reports ( Di Domenico et al. ). Currently, one of the primary interest of the lab is to investigate the involvement of reactive astrocytes in the pathophysiology of PD. An understanding of how chronic inflammation contribute to the degeneration of dopaminergic neurons and to the progression of PD is important, as such information is likely to facilitate the development of novel and more efficacious therapies for PD.
Overall’s research group takes advantage of a variety of experimental paradigms, approached from a multi- disciplinary perspective, ranging from bioengineering approaches to 3D stem cell differentiation to single-cell genetic lineage tracing analyses and genetic manipulation of human cells. The lab aimed at tackling important current issues in biology and biomedicine, such as the mechanisms that control the establishment and maintenance of developmental potency, the initiation and progression of the regenerative process, and the differentiation and functional maturation of human neurons and astrocytes, and the development of genuinely human models of human disease.
Publications: Dr. Consiglio is the author or co-author of 39 publications in peer-reviewed journals with a cumulative impact factor of 334.82 (ISI). Cumulative citation index: 5133 (ISI). Average citations per article: 134.55 (ISI). h-Index: 22 (ISI). (https://www.ncbi.nlm.nih.gov/pubmed/?term=antonella+consiglio).
R+D projects from public funding (ongoing or completed, last 5 years):
- RD16/0011/0024: Red de Terapia Celular (TerCel). Funding entity ISCIII Health Institute, FEDER (2017-2021) PI: A. Raya. Co-PI: A. Consiglio.
- BFU2016-80870-P: Molecular, cellular and functional characterization of Parkinson's disease patient-specific iPS cell-derived dopaminergic neurons. Funding entity: Spanish Research Ministry (2017-2019).
PI: A. Consiglio.
- StG-311736-PD-HUMMODEL: “Elucidating early pathogenic mechanisms of neurodegeneration in Parkinson's disease through a humanized dynamic in vitro model”. Funding entity: European Research Council (ERC) (2013- 2019). PI: A. Consiglio.
- 2017 SGR 899: Advanced modeling of human disease through iPS cell technology. Funding entity: AGAUR (Agència de Gestió d’Ajuts Univ.i de Recerca - Generalitat de Catalunya (2018-2020).
PI: A. Raya. Co-PI: A.Consiglio.
- BFU2013-49157-P: Using human stem cells to investigate the pathogenesis of Parkinson’s disease. Funding entity: Spanish Research Ministry (2014-2016).
PI: A. Consiglio.
Utilizzo di cellule staminali pluripotenti umane e dei loro progenitori neurali per il trattamento di tumori cerebrali maligni.. Funding entity: Fondazione G. Berlucchi per la Ricerca sul Cancro (2011-2013).
PI: A. Consiglio
- BFU2010-21823: Modeling neurodegenerative pathology through disease-specific induced pluripotent stem cells. Funding entity: Spanish Research Ministry (2010-2013).PI: A. Consiglio.
- CP05/00294, Project associated to Contract: In vivo tracking of neural stem cells and their progeny by lentiviral vectors: evaluation of their potential contribution to the treatment of neurodegenerative disorders. Funding entity: Spanish Health Ministry (2006-2009), Spain).PI: A. Consiglio
- Marató TV3 (n.63430): Cellular and molecular bases and functional implications of adult hippocampal neurogenesis; implications for the pathogenesis Alzheimer's disease (2007-2010). PI: J.C. Belmonte. Co-PI: A. Consiglio.
Scientific collaborations:
• Prof. Angel Raya (Control of Stem Cell Potency Group, CMRB, Barcelona), Dr. Isidre Ferrer (Institut de Neuropatologia, IDIBELL, Barcelona); Dr. Antonio Zorzano (Complex metabolic diseases and mitochondria, IRB, Barcelona), Dr. Manuel Juan Otero (Inmunology, Hospital Clinic, Barcelona), Prof. Eduardo Tolosa (IDIBAPS, Hospital Clinic, Barcelona), Prof. Ernest Giralt (Design, synthesis and structure of peptides, IRB, Barcelona), Dra. Anna M. Planas (Investigación cerebrovascular, IIBB, Barcelona), Prof. J. López Barneo (Instituto de Biomedicina de Sevilla, IBIS, Sevilla), Prof. Isabel Fariñas (Departamento de Biología Celular, Universidad de Valencia, Valencia), Prof. Jordi Alberch (IDIBAPS, Hospital Clínic, Barcelona), Dr. Miquel Vila (Neurodegenerative Diseases Research Group, University Hospital Vall d’Hebron, Barcelona).
• International collaborators: Dr. Brian Kaspar (Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital, Ohio State University), Prof. A. Muotri (Department of Cellular and Molecular Medicine, UCSD, San Diego, USA), Prof. Sebastian Jessberger (Brain Research Institute / HiFo Laboratory of Neural Plasticity, University of Zurich, Zurich, Switzerland), Prof. Hans Scholer (Max Planck Institute for Molecular Biomedicine, Münster, Germany), Dr. A.M. Cuervo (Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York), Prof. Toni Cathomen (University Medical Centre, Freiburg, Germany), Dr. Kinichi Nakashima(Graduate School of Medical Sciences, Kyushu University, Japan), Prof. Fred H. Gage (The Salk Institute for Biological Studies, La Jolla, CA).
Ricercatore di Biochimica Clinica e Biologia Molecolare Clinica,
Dipartimento di Scienze Biomediche e Biotecnologiche,
Viale Europa, 11-25123 Brescia
Telefono: 030/3717.553 – 030/3717.545-561
Fax: 030/3701157
E-mail: consiglio@med.unibs.it aconsiglio@ibub.pcb.ub.es
Consiglio lab uses stem cells, mainly patient-derived induced pluripotent stem cells (iPSCs) derived from idiopathic and familial PD skin cells and healthy age-matched controls, aiming to decipher the mechanisms that lead to PD brain cell dysfunction and degeneration. The lab is also developing novel technologies in stem cells, genetic cell reprogramming and CRISPR/Cas9 gene editing for modeling other neurodegenerative diseases as well as exploring the potential of iPSC-based strategies for biomedical applications for neurodegenerative diseases, in particular for PD.
Dr. Consiglio received her PhD degree in Cellular and Molecular Pathology at the San Raffaele Scientific Hospital, DIBIT (Italy), and additional training at Gene Therapy Center of Lausanne (Switzerland) and Vectors Technology Laboratory at Cell Genesys (Foster City, CA). She did her Postdoctoral research at the Salk Institute for Biological Studies in La Jolla (USA) in the laboratory of one of the leaders in the neurogenesis field, Prof. F.H. Gage. From 2006 to 2009 Dr. Consiglio conducted her research in the Center of Regenerative Medicine in Barcelona (CMRB), where she started a close collaboration with the group directed by Prof. J.C. Izpisúa-Belmonte. During this period, she made notable contributions to the fields of neurogenesis, as well as pluripotent stem cell biology and neural differentiation that resulted in publications in top-tier scientific journals. In addition, Dr. Consiglio and her team carried out specific projects aimed at uncovering the signaling molecules that instruct neural stem/progenitor cells to differentiate toward specific cell types. Among the contributions from this research period are: the successful derivation and characterisation of hES cell lines, (CSH, 2008), and the efficient generation of iPSCs from human keratinocytes (Nat. Biotech, 2008, Genes & Development, 2010), and 3. the first generation of patient- specific iPSCs (Nature, 2009). Other studies examined the developmental potential of iPS cells necessary to validate their usage in cell replacement strategies (Aging Cell, 2012; Stem Cell Dev., 2012). Interestingly, her research group unequivocally demonstrated that stable genetic engineering of hESC/iPSC with lentiviral vectors driving controlled expression of LMX1A is an efficient way to generate enriched populations of human A9-subtype ventral midbrain DA neurons that can survive and differentiate when grafted into the brain of adult mice (Human Gene Therapy, 2012).
In 2013 A. Consiglio has been awarded a European Research Council (ERC) Starting Independent Researcher by the EU. Some of the scientific highlights of the group within the last five years include the study of how neural stem cells can be directed to mature functioning nerve cells in the adult brain and their potential in physiology and disease. By using several approaches, including exogenously regulated expression, LV-mediated siRNA delivery, constitutive, conditional and self- excising LV mediated delivery, the function of several candidate genes have been investigated in vivo to explore new strategies for the selective amplification of transduced cells, forced differentiation toward cell lineages or forced migration toward diseases sites (Nat. Cell Biology, 2014). In addition, Consiglio lab in collaboration with the group of Dr. Angel Raya (Center of Regenerative Medicine in Barcelona), and Dr. Eduard Tolosa (Hospital Clinic, Barcelona) developed a human cell-based model for PD using induced pluripotent stem cells (iPSC) from patients suffering sporadic or familial PD, and age-matched controls, to generate patient-specific dopamine neurons (DAn). Interestingly we found that patients’ DAn show PD-relevant phenotypes such as abnormal α-synuclein accumulation, alterations in the autophagy machinery, and increased susceptibility to undergo neurodegeneration upon long-term culture. All our achievements collected in the recent studies, confirm the possibility that the new developed PD humanized in vitro model will allow the straightforward investigation of the cellular defects associated with PD providing an ideal setting for future systematic drug screenings. The results of the research team during the last five years have been published in several international peer-reviewed journals (EMBO Mol. Med, 2012; Nat. Neurosc., 2013; EMBO Mol. Med. 2015; Stem Cell Reports, 2015; Molecular Neurobiology, 2018; Cell Reports, under revision).
Dr. Consiglio is a reviewer for several journals including: Nature, Nature Neuroscience, Neurobiology of Disease, Scientific Reports, PNAS, Autophagy, Neurology and Brain. She also acted as Ad-hoc reviewer for funding agencies including: ANEP (Spanish National Agency for Grant Evaluation); AGAUR (Catalonian Agency for Grant Evaluation); INSERM (France); Italian Ministry of Instruction, University and Research (MIUR), TELETHON (Italy) and European Research Council (ERC).
Dr. Consiglio is member of several societies including: American Society of Gene and Cell Therapy (since 2000); European Society of Gene and Cell Therapy (since 2008), Society for Neuroscience (since 2003), International Society for Stem Cell Research (since 2008), FENS (since 2010); Italian Society for Neuroscience (SINS, Italy) (since 2007): Spanish Society for Cell and Gene Therapy (since 2012). Antonella Consiglio is also a Founder and Board Member of the Stem Cell Research (SCR, Italy).
On the last topics, Dr. Consiglio’s group has recently provided the first direct experimental evidence that astrocytes from PD patients not only produce significantly more α-synuclein than astrocytes from healthy individuals, but also manifest many pathological changes typical of PD. Interestingly, PD astrocytes contribute to a selective vmDA neuronal cell death, suggesting that they play a key role in the early stages of the disease. A manuscript reporting these ground-breaking observations is currently in the second revision stage in Cell Reports ( Di Domenico et al. ). Currently, one of the primary interest of the lab is to investigate the involvement of reactive astrocytes in the pathophysiology of PD. An understanding of how chronic inflammation contribute to the degeneration of dopaminergic neurons and to the progression of PD is important, as such information is likely to facilitate the development of novel and more efficacious therapies for PD.
Overall’s research group takes advantage of a variety of experimental paradigms, approached from a multi- disciplinary perspective, ranging from bioengineering approaches to 3D stem cell differentiation to single-cell genetic lineage tracing analyses and genetic manipulation of human cells. The lab aimed at tackling important current issues in biology and biomedicine, such as the mechanisms that control the establishment and maintenance of developmental potency, the initiation and progression of the regenerative process, and the differentiation and functional maturation of human neurons and astrocytes, and the development of genuinely human models of human disease.
Publications: Dr. Consiglio is the author or co-author of 39 publications in peer-reviewed journals with a cumulative impact factor of 334.82 (ISI). Cumulative citation index: 5133 (ISI). Average citations per article: 134.55 (ISI). h-Index: 22 (ISI). (https://www.ncbi.nlm.nih.gov/pubmed/?term=antonella+consiglio).
R+D projects from public funding (ongoing or completed, last 5 years):
- RD16/0011/0024: Red de Terapia Celular (TerCel). Funding entity ISCIII Health Institute, FEDER (2017-2021) PI: A. Raya. Co-PI: A. Consiglio.
- BFU2016-80870-P: Molecular, cellular and functional characterization of Parkinson's disease patient-specific iPS cell-derived dopaminergic neurons. Funding entity: Spanish Research Ministry (2017-2019).
PI: A. Consiglio.
- StG-311736-PD-HUMMODEL: “Elucidating early pathogenic mechanisms of neurodegeneration in Parkinson's disease through a humanized dynamic in vitro model”. Funding entity: European Research Council (ERC) (2013- 2019). PI: A. Consiglio.
- 2017 SGR 899: Advanced modeling of human disease through iPS cell technology. Funding entity: AGAUR (Agència de Gestió d’Ajuts Univ.i de Recerca - Generalitat de Catalunya (2018-2020).
PI: A. Raya. Co-PI: A.Consiglio.
- BFU2013-49157-P: Using human stem cells to investigate the pathogenesis of Parkinson’s disease. Funding entity: Spanish Research Ministry (2014-2016).
PI: A. Consiglio.
Utilizzo di cellule staminali pluripotenti umane e dei loro progenitori neurali per il trattamento di tumori cerebrali maligni.. Funding entity: Fondazione G. Berlucchi per la Ricerca sul Cancro (2011-2013).
PI: A. Consiglio
- BFU2010-21823: Modeling neurodegenerative pathology through disease-specific induced pluripotent stem cells. Funding entity: Spanish Research Ministry (2010-2013).PI: A. Consiglio.
- CP05/00294, Project associated to Contract: In vivo tracking of neural stem cells and their progeny by lentiviral vectors: evaluation of their potential contribution to the treatment of neurodegenerative disorders. Funding entity: Spanish Health Ministry (2006-2009), Spain).PI: A. Consiglio
- Marató TV3 (n.63430): Cellular and molecular bases and functional implications of adult hippocampal neurogenesis; implications for the pathogenesis Alzheimer's disease (2007-2010). PI: J.C. Belmonte. Co-PI: A. Consiglio.
Scientific collaborations:
• Prof. Angel Raya (Control of Stem Cell Potency Group, CMRB, Barcelona), Dr. Isidre Ferrer (Institut de Neuropatologia, IDIBELL, Barcelona); Dr. Antonio Zorzano (Complex metabolic diseases and mitochondria, IRB, Barcelona), Dr. Manuel Juan Otero (Inmunology, Hospital Clinic, Barcelona), Prof. Eduardo Tolosa (IDIBAPS, Hospital Clinic, Barcelona), Prof. Ernest Giralt (Design, synthesis and structure of peptides, IRB, Barcelona), Dra. Anna M. Planas (Investigación cerebrovascular, IIBB, Barcelona), Prof. J. López Barneo (Instituto de Biomedicina de Sevilla, IBIS, Sevilla), Prof. Isabel Fariñas (Departamento de Biología Celular, Universidad de Valencia, Valencia), Prof. Jordi Alberch (IDIBAPS, Hospital Clínic, Barcelona), Dr. Miquel Vila (Neurodegenerative Diseases Research Group, University Hospital Vall d’Hebron, Barcelona).
• International collaborators: Dr. Brian Kaspar (Center for Gene Therapy at The Research Institute at Nationwide Children’s Hospital, Ohio State University), Prof. A. Muotri (Department of Cellular and Molecular Medicine, UCSD, San Diego, USA), Prof. Sebastian Jessberger (Brain Research Institute / HiFo Laboratory of Neural Plasticity, University of Zurich, Zurich, Switzerland), Prof. Hans Scholer (Max Planck Institute for Molecular Biomedicine, Münster, Germany), Dr. A.M. Cuervo (Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York), Prof. Toni Cathomen (University Medical Centre, Freiburg, Germany), Dr. Kinichi Nakashima(Graduate School of Medical Sciences, Kyushu University, Japan), Prof. Fred H. Gage (The Salk Institute for Biological Studies, La Jolla, CA).
Pubblicazioni (58)
Insegnamenti offerta formativa corrente
1 CFU
15 ore
No Results Found